Overview

Pembrolizumab in High-risk Thyroid Cancer

Status:
Not yet recruiting

Trial end date:
2027-12-01

Target enrollment:

Participant gender:

Summary

This window of opportunity trial is studying a checkpoint inhibitor agent to treat differentiated thyroid cancer in a neoadjuvant setting. A checkpoint inhibitor is a compound aimed at restoring tumor immunosurveillance. The name of this agent is pembrolizumab.

Phase:

Phase 2

Details

Lead Sponsor:

Istituti Clinici Scientifici Maugeri SpA

Collaborator:

Merck Sharp & Dohme LLC

Treatments:

Pembrolizumab